Eli Lilly and Company LLY
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 27.58B | 26.71B | 25.28B | 20.64B | 18.41B |
| Total Depreciation and Amortization | 2.17B | 2.10B | 2.04B | 2.00B | 1.90B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.46B | 4.07B | -446.70M | 2.27B | 2.40B |
| Change in Net Operating Assets | -5.57B | -4.80B | -6.39B | -8.09B | -6.64B |
| Cash from Operations | 30.64B | 28.08B | 20.48B | 16.81B | 16.06B |
| Capital Expenditure | -10.98B | -9.89B | -8.66B | -7.84B | -6.79B |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -10.80B | -10.47B | -1.72B | -660.60M | -549.30M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -8.63B | -4.74B | -1.16B | -2.47B | -2.75B |
| Cash from Investing | -30.41B | -25.10B | -11.53B | -10.97B | -10.09B |
| Total Debt Issued | 8.94B | 20.93B | 8.48B | 13.17B | 13.17B |
| Total Debt Repaid | -1.62B | -5.72B | -4.02B | -5.12B | -2.07B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -5.84B | -6.17B | -5.26B | -4.11B | -4.65B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -5.98B | -5.79B | -5.59B | -5.38B | -5.21B |
| Other Financing Activities | -637.10M | -649.10M | -676.10M | -771.10M | -791.90M |
| Cash from Financing | -5.14B | 2.61B | -7.06B | -2.21B | 440.50M |
| Foreign Exchange rate Adjustments | 3.90M | -20.10M | 306.90M | 371.90M | 10.20M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.91B | 5.57B | 2.19B | 4.00B | 6.42B |